Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Phase 3

Completed

• Conditions: Haemophilus Influenzae Type b; Neisseria Meningitidis

• Registration Number: NCT00345683
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age.

This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579).

No new recruitment will take place during this booster phase of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Detailed Description

Hib-MenCY-TT = GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.

The study will be conducted in a single blind manner up to 30 days after administration of the booster dose; the extended safety follow-up after the booster dose will be conducted in an unblinded manner.

All subjects will receive Prevnar, M-M-R II and Varivax as study vaccines, preferencially co-administered with the booster dose of Hib-MenCY-TT/PedvaxHIB.

Note: This protocol posting deals with the objectives \& outcome measures for the booster phase of the study. The objectives \& outcome measures for the primary phase are presented in a separate protocol posting (NCT00345579)

Study Timeline

• Study First Submitted: 2006-06-26
• Study First Submitted QC: 2006-06-26
• Study First Posted: 2006-06-28
• Study Start: 2007-07
• Primary Completion: 2008-09
• Study Completion: 2008-11
• Disposition First Submitted: 2009-06-08
• Disposition First Submitted QC: 2009-09-28
• Disposition First Posted: 2009-09-30
• Results First Submitted: 2012-06-15
• Results First Submitted QC: 2012-06-15
• Results First Posted: 2012-07-20
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-18
• Last Update Posted: 2016-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4021

Inclusion Criteria

• Subjects enrolled in the primary study (NCT00345579) are eligible for participating in the booster study

Exclusion Criteria

Subjects should not be administered M-M-R II and Varivax if any of these criteria apply:

• History of measles, mumps, rubella or varicella.
• Previous vaccination against measles, mumps, rubella or varicella.
• Hypersensitivity to any component of the vaccines, including gelatin or neomycin.
• Patients receiving immunosuppressive therapy.
• Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.
• Individuals with primary and acquired immunodeficiency states.
• Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
• Individuals with active tuberculosis.
• Acute disease at time of booster vaccination

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)	From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)	NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.
Number of Subjects With Adverse Events Resulting in Emergency Room (ER) Visits	From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
Number of Subjects Reporting Serious Adverse Events (SAEs)	From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Number of Subjects Reporting Rash	From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)	Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae
Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits	From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
Number of Subjects With Serious Adverse Events (SAEs)	From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Number of Subjects With New Onset of Chronic Illnesses (NOCIs)	From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)	NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.
Number of Subjects With Rash	From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)	Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae

Trial Locations

Locations (1)

GSK Investigational Site; 🇲🇽 Mexico, D.F., Mexico

GSK Investigational Site

🇲🇽Mexico, D.F., Mexico